CAR--话题@MedSci

#CAR-#

459篇内容 | 2589人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1781379, encodeId=bfd11e8137966, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=Immunity：可循环CAR-T细胞有望具有更强大的抗肿瘤作用, objectType=article, longId=199836, objectId=9702199836cc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9702199836cc, replyNumber=0, likeNumber=71, createdTime=2021-01-09, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9702199836cc, moduleTitle=Immunity：可循环CAR-T细胞有望具有更强大的抗肿瘤作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9702199836cc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781396, encodeId=f7a21e813965a, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=治疗急性淋巴细胞白血病，合源生物CAR-T疗法拟纳入突破性治疗品种, objectType=article, longId=204505, objectId=f42b2045051f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f42b2045051f, replyNumber=0, likeNumber=80, createdTime=2021-05-28, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f42b2045051f, moduleTitle=治疗急性淋巴细胞白血病，合源生物CAR-T疗法拟纳入突破性治疗品种, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f42b2045051f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781406, encodeId=14d61e8140690, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=Nat Commun：地西他滨处理CAR-T细胞，能增强其抗肿瘤活性, objectType=article, longId=206197, objectId=a7aa20619ebe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a7aa20619ebe, replyNumber=0, likeNumber=76, createdTime=2021-10-02, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a7aa20619ebe, moduleTitle=Nat Commun：地西他滨处理CAR-T细胞，能增强其抗肿瘤活性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a7aa20619ebe)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781395, encodeId=23401e8139507, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=CRISPR编辑的CAR-T细胞疗法增强了对抗血癌的能力, objectType=article, longId=204328, objectId=6b2e20432812, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6b2e20432812, replyNumber=0, likeNumber=71, createdTime=2021-01-24, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6b2e20432812, moduleTitle=CRISPR编辑的CAR-T细胞疗法增强了对抗血癌的能力, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6b2e20432812)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781392, encodeId=db411e8139298, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=FDA暂停CAR-T疗法UCARTCS1治疗多发性骨髓瘤的临床试验, objectType=article, longId=203554, objectId=dd3d2035543d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dd3d2035543d, replyNumber=0, likeNumber=66, createdTime=2021-05-17, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dd3d2035543d, moduleTitle=FDA暂停CAR-T疗法UCARTCS1治疗多发性骨髓瘤的临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dd3d2035543d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781430, encodeId=edf31e81430b0, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=Nature Reviews Drug Discovery：攻克实体瘤，CAR-T疗法还需面对哪些挑战？, objectType=article, longId=212116, objectId=5d0121211631, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5d0121211631, replyNumber=0, likeNumber=83, createdTime=2022-04-11, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5d0121211631, moduleTitle=Nature Reviews Drug Discovery：攻克实体瘤，CAR-T疗法还需面对哪些挑战？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5d0121211631)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781427, encodeId=86eb1e81427b0, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=Clin Lymphoma Myeloma Leuk：CAR-T疗法可用于治疗异体造血干细胞移植后复发/难治的B细胞急淋白血病患者, objectType=article, longId=210737, objectId=56f3210e371b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=56f3210e371b, replyNumber=0, likeNumber=73, createdTime=2021-08-12, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=56f3210e371b, moduleTitle=Clin Lymphoma Myeloma Leuk：CAR-T疗法可用于治疗异体造血干细胞移植后复发/难治的B细胞急淋白血病患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=56f3210e371b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781369, encodeId=4c2d1e813690c, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=国内CAR-T CD276靶点的细胞疗法或能攻克实体瘤, objectType=article, longId=197905, objectId=be9419e905b1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=be9419e905b1, replyNumber=0, likeNumber=66, createdTime=2021-06-08, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=be9419e905b1, moduleTitle=国内CAR-T CD276靶点的细胞疗法或能攻克实体瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=be9419e905b1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781404, encodeId=3f3b1e8140485, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=不是CAR-T/NK/M，新型细胞治疗技术来了，目标是攻克实体瘤！, objectType=article, longId=206015, objectId=de1e20601538, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=de1e20601538, replyNumber=0, likeNumber=61, createdTime=2021-03-17, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=de1e20601538, moduleTitle=不是CAR-T/NK/M，新型细胞治疗技术来了，目标是攻克实体瘤！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=de1e20601538)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781382, encodeId=cc6e1e8138288, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=CDE公示第4个拟突破性治疗品种：药明巨诺CAR-T疗法, objectType=article, longId=200518, objectId=c7512005180b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c7512005180b, replyNumber=0, likeNumber=56, createdTime=2021-05-20, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c7512005180b, moduleTitle=CDE公示第4个拟突破性治疗品种：药明巨诺CAR-T疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c7512005180b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781391, encodeId=6c611e813911d, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=CAR-T细胞免疫疗法临床研究与伦理审查实践, objectType=article, longId=202609, objectId=56f8202609e1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=56f8202609e1, replyNumber=0, likeNumber=88, createdTime=2021-09-11, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=56f8202609e1, moduleTitle=CAR-T细胞免疫疗法临床研究与伦理审查实践, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=56f8202609e1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781409, encodeId=a9c71e81409f2, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=Artiva Biotherapeutics宣布与默克公司达成**全球合作和许可协议，以开发候选CAR-NK细胞疗法, objectType=article, longId=206408, objectId=55db20640853, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=55db20640853, replyNumber=0, likeNumber=75, createdTime=2021-05-13, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=55db20640853, moduleTitle=Artiva Biotherapeutics宣布与默克公司达成**全球合作和许可协议，以开发候选CAR-NK细胞疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=55db20640853)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781426, encodeId=83131e81426f6, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=Nat Commun：BCMA/CS1双特异性CAR可防止CAR-T治疗MM时抗原逃逸的发生, objectType=article, longId=210731, objectId=7ac5210e3109, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7ac5210e3109, replyNumber=0, likeNumber=103, createdTime=2021-09-21, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7ac5210e3109, moduleTitle=Nat Commun：BCMA/CS1双特异性CAR可防止CAR-T治疗MM时抗原逃逸的发生, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7ac5210e3109)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781390, encodeId=4abf1e813900e, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=托珠单抗中国获批用于治疗CAR-T疗法引起的细胞因子风暴, objectType=article, longId=202484, objectId=32e7202484ec, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=32e7202484ec, replyNumber=0, likeNumber=90, createdTime=2021-03-16, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=32e7202484ec, moduleTitle=托珠单抗中国获批用于治疗CAR-T疗法引起的细胞因子风暴, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=32e7202484ec)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781423, encodeId=13711e81423af, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=日本厚生劳动省批准CAR-T细胞疗法Breyanzi治疗DLBCL和滤泡性淋巴瘤, objectType=article, longId=209158, objectId=40ec209158b9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=40ec209158b9, replyNumber=0, likeNumber=73, createdTime=2021-12-29, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=40ec209158b9, moduleTitle=日本厚生劳动省批准CAR-T细胞疗法Breyanzi治疗DLBCL和滤泡性淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=40ec209158b9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781388, encodeId=cbac1e8138865, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=CAR-T细胞疗法MB-102治疗BPDCN、AML、hrMDS：即将开展多中心I/II期临床试验, objectType=article, longId=201543, objectId=a72820154315, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a72820154315, replyNumber=0, likeNumber=91, createdTime=2021-09-05, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a72820154315, moduleTitle=CAR-T细胞疗法MB-102治疗BPDCN、AML、hrMDS：即将开展多中心I/II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a72820154315)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781375, encodeId=ff701e81375d9, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=诺华CAR-T疗法Kymriah：达到滤泡性淋巴瘤试验终点, objectType=article, longId=198822, objectId=494f19882295, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=494f19882295, replyNumber=0, likeNumber=68, createdTime=2021-05-08, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=494f19882295, moduleTitle=诺华CAR-T疗法Kymriah：达到滤泡性淋巴瘤试验终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=494f19882295)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781420, encodeId=ea051e814202f, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=Nat Commun：CD318、TSPAN8和CD66c为胰腺癌CAR-T细胞疗法的候选靶标, objectType=article, longId=208290, objectId=058f2082904e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=058f2082904e, replyNumber=0, likeNumber=84, createdTime=2021-11-03, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=058f2082904e, moduleTitle=Nat Commun：CD318、TSPAN8和CD66c为胰腺癌CAR-T细胞疗法的候选靶标, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=058f2082904e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781366, encodeId=34c91e813667b, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=FDA批准双开关CAR-T细胞治疗进入临床, objectType=article, longId=196208, objectId=a120196208a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a120196208a6, replyNumber=0, likeNumber=63, createdTime=2021-03-02, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a120196208a6, moduleTitle=FDA批准双开关CAR-T细胞治疗进入临床, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a120196208a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781401, encodeId=41d71e8140114, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=恒润达生CD19/CD22双靶点CAR-T疗法获批临床, objectType=article, longId=205478, objectId=80262054e8b4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=80262054e8b4, replyNumber=0, likeNumber=58, createdTime=2021-08-05, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=80262054e8b4, moduleTitle=恒润达生CD19/CD22双靶点CAR-T疗法获批临床, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=80262054e8b4)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

CAR-

2020-05-29

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

Immunity：可循环CAR-T细胞有望具有更强大的抗肿瘤作用

2021-01-09

智者为医08 (审核中...)

前往app查看评论内容

#CAR-#

治疗急性淋巴细胞白血病，合源生物CAR-T疗法拟纳入突破性治疗品种

2021-05-28

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

Nat Commun：地西他滨处理CAR-T细胞，能增强其抗肿瘤活性

2021-10-02

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

CRISPR编辑的CAR-T细胞疗法增强了对抗血癌的能力

2021-01-24

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

FDA暂停CAR-T疗法UCARTCS1治疗多发性骨髓瘤的临床试验

2021-05-17

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

Nature Reviews Drug Discovery：攻克实体瘤，CAR-T疗法还需面对哪些挑战？

2022-04-11

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

Clin Lymphoma Myeloma Leuk：CAR-T疗法可用于治疗异体造血干细胞移植后复发/难治的B细胞急淋白血病患者

2021-08-12

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

国内CAR-T CD276靶点的细胞疗法或能攻克实体瘤

2021-06-08

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

不是CAR-T/NK/M，新型细胞治疗技术来了，目标是攻克实体瘤！

2021-03-17

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

CDE公示第4个拟突破性治疗品种：药明巨诺CAR-T疗法

2021-05-20

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

CAR-T细胞免疫疗法临床研究与伦理审查实践

2021-09-11

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

Artiva Biotherapeutics宣布与默克公司达成**全球合作和许可协议，以开发候选CAR-NK细胞疗法

2021-05-13

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

Nat Commun：BCMA/CS1双特异性CAR可防止CAR-T治疗MM时抗原逃逸的发生

2021-09-21

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

托珠单抗中国获批用于治疗CAR-T疗法引起的细胞因子风暴

2021-03-16

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

日本厚生劳动省批准CAR-T细胞疗法Breyanzi治疗DLBCL和滤泡性淋巴瘤

2021-12-29

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

CAR-T细胞疗法MB-102治疗BPDCN、AML、hrMDS：即将开展多中心I/II期临床试验

2021-09-05

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

诺华CAR-T疗法Kymriah：达到滤泡性淋巴瘤试验终点

2021-05-08

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

Nat Commun：CD318、TSPAN8和CD66c为胰腺癌CAR-T细胞疗法的候选靶标

2021-11-03

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

FDA批准双开关CAR-T细胞治疗进入临床

2021-03-02

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

恒润达生CD19/CD22双靶点CAR-T疗法获批临床

2021-08-05

科室
- - 订阅+
  - 更多科室
工具
服务